Bhavana Konda1, Lawrence S Kirschner. 1. aDivision of OncologybDivision of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, The Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA.
Abstract
PURPOSE OF REVIEW: Adrenocortical carcinoma is a rare cancer, but one that carries a poor prognosis due to its aggressive nature and unresponsiveness to conventional chemotherapeutic strategies. Over the past 12 years, there has been renewed interest in developing new therapies for this cancer, including identifying key signaling nodes responsible for cell proliferation. RECENT FINDINGS: Clinical trials of tyrosine kinase inhibitors as monotherapy have generally been disappointing, although the identification of exceptional responders may lead to the identification of targeted therapies that may produce responses in subsets of patients. Agents targeted to the Wnt signaling pathway, a known player in adrenal carcinogenesis, have been developed, although they have not yet been used specifically for adrenal cancer. There is current excitement about inhibitors of acetyl-coA cholesterol acetyl transferase 1, an enzyme required for intracellular cholesterol handling, although trials are still underway. Tools to target other proteins such as Steroidogenic Factor 1 and mechanistic target of rapamycin have been developed and are moving towards clinical application. SUMMARY: Progress is being made in the fight against adrenocortical carcinoma with the identification of new therapeutic targets and new means by which to attack them. Continued improvement in the prognosis for patients with adrenal cancer is expected as this research continues.
PURPOSE OF REVIEW: Adrenocortical carcinoma is a rare cancer, but one that carries a poor prognosis due to its aggressive nature and unresponsiveness to conventional chemotherapeutic strategies. Over the past 12 years, there has been renewed interest in developing new therapies for this cancer, including identifying key signaling nodes responsible for cell proliferation. RECENT FINDINGS: Clinical trials of tyrosine kinase inhibitors as monotherapy have generally been disappointing, although the identification of exceptional responders may lead to the identification of targeted therapies that may produce responses in subsets of patients. Agents targeted to the Wnt signaling pathway, a known player in adrenal carcinogenesis, have been developed, although they have not yet been used specifically for adrenal cancer. There is current excitement about inhibitors of acetyl-coA cholesterol acetyl transferase 1, an enzyme required for intracellular cholesterol handling, although trials are still underway. Tools to target other proteins such as Steroidogenic Factor 1 and mechanistic target of rapamycin have been developed and are moving towards clinical application. SUMMARY: Progress is being made in the fight against adrenocortical carcinoma with the identification of new therapeutic targets and new means by which to attack them. Continued improvement in the prognosis for patients with adrenal cancer is expected as this research continues.
Authors: D E Schteingart; G M Doherty; P G Gauger; T J Giordano; G D Hammer; M Korobkin; F P Worden Journal: Endocr Relat Cancer Date: 2005-09 Impact factor: 5.678
Authors: Timothy A Yap; David Olmos; Andre T Brunetto; Nina Tunariu; Jorge Barriuso; Ruth Riisnaes; Lorna Pope; Jeremy Clark; Andrew Futreal; Michael Germuska; David Collins; Nandita M deSouza; Martin O Leach; Ronald E Savage; Carol Waghorne; Feng Chai; Edward Garmey; Brian Schwartz; Stan B Kaye; Johann S de Bono Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: L Ghataore; I Chakraborti; S J Aylwin; K-M Schulte; D Dworakowska; P Coskeran; N F Taylor Journal: Endocr Connect Date: 2012-07-21 Impact factor: 3.335
Authors: Barbara Kiesewetter; Philipp Riss; Christian Scheuba; Peter Mazal; Elisabeth Kretschmer-Chott; Alexander Haug; Markus Raderer Journal: Ther Adv Med Oncol Date: 2021-08-31 Impact factor: 5.485